ZCM
ENTA icon

Zebra Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Zebra Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,875
Closed -$239K – 244
2019
Q4 		$239K Buy
+3,875
New +$240K 0.21% 199

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Zebra Capital Management's ENTA Position: Q1 2020 in Review

Zebra Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q1 2020, closing a stake of 3,875 shares — an estimated $239K sold.

Zebra Capital Management first reported a position in ENTA in Q4 2019 and held it in 1 quarter. The position peaked at $239K in Q4 2019. 156 funds tracked by Wall St. Rank hold ENTA as of Q1 2020.

  • Zebra Capital Management reported no remaining Enanta Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Zebra Capital Management sold 3,875 Enanta Pharmaceuticals shares in Q1 2020, an estimated $239K.
  • Zebra Capital Management first reported a position in Enanta Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Zebra Capital Management's Enanta Pharmaceuticals position peaked at $239K in Q4 2019.
  • 156 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2020.

Based on Zebra Capital Management's 13F filing for Q1 2020, filed 15 May 2020.